These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16715134)

  • 21. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis.
    Wang J; Yang Y; Xia HH; Gu Q; Lin MC; Jiang B; Peng Y; Li G; An X; Zhang Y; Zhuang Z; Zhang Z; Kung HF; Wong BC
    Gastroenterology; 2007 Mar; 132(3):1066-76. PubMed ID: 17383428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
    Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
    Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
    Kim CH; Kim J; Kahng H; Choi EC
    Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
    Soltermann A; Tischler V; Arbogast S; Braun J; Probst-Hensch N; Weder W; Moch H; Kristiansen G
    Clin Cancer Res; 2008 Nov; 14(22):7430-7. PubMed ID: 19010860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells.
    Billottet C; Tuefferd M; Gentien D; Rapinat A; Thiery JP; Broët P; Jouanneau J
    J Cell Biochem; 2008 Jun; 104(3):826-39. PubMed ID: 18189245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rho isoforms have distinct and specific functions in the process of epithelial to mesenchymal transition in renal proximal tubular cells.
    Hutchison N; Hendry BM; Sharpe CC
    Cell Signal; 2009 Oct; 21(10):1522-31. PubMed ID: 19477269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of RHOC is associated with metastasis of gastric carcinomas.
    Kondo T; Sentani K; Oue N; Yoshida K; Nakayama H; Yasui W
    Pathobiology; 2004; 71(1):19-25. PubMed ID: 14555841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
    Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
    Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells.
    Wang Q; Sun Z; Yang HS
    Oncogene; 2008 Mar; 27(11):1527-35. PubMed ID: 17828298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of RhoA in progression of human hepatocellular carcinoma.
    Wang D; Dou K; Xiang H; Song Z; Zhao Q; Chen Y; Li Y
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1916-20. PubMed ID: 17914970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC.
    Kitzing TM; Wang Y; Pertz O; Copeland JW; Grosse R
    Oncogene; 2010 Apr; 29(16):2441-8. PubMed ID: 20101212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma.
    Li XR; Ji F; Ouyang J; Wu W; Qian LY; Yang KY
    Eur J Surg Oncol; 2006 Dec; 32(10):1130-4. PubMed ID: 16806792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition.
    Mejlvang J; Kriajevska M; Berditchevski F; Bronstein I; Lukanidin EM; Pringle JH; Mellon JK; Tulchinsky EM
    Exp Cell Res; 2007 Jan; 313(2):380-93. PubMed ID: 17141758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing of RhoA and RhoC expression by RNA interference suppresses human colorectal carcinoma growth in vivo.
    Wang H; Zhao G; Liu X; Sui A; Yang K; Yao R; Wang Z; Shi Q
    J Exp Clin Cancer Res; 2010 Sep; 29(1):123. PubMed ID: 20828398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA.
    Tabu K; Ohba Y; Suzuki T; Makino Y; Kimura T; Ohnishi A; Sakai M; Watanabe T; Tanaka S; Sawa H
    Mol Cancer Res; 2007 Oct; 5(10):1099-109. PubMed ID: 17951409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway.
    Cao XX; Xu JD; Xu JW; Liu XL; Cheng YY; Li QQ; Xu ZD; Liu XP
    Breast Cancer Res Treat; 2011 Apr; 126(3):555-63. PubMed ID: 20499158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.
    Horiuchi A; Imai T; Wang C; Ohira S; Feng Y; Nikaido T; Konishi I
    Lab Invest; 2003 Jun; 83(6):861-70. PubMed ID: 12808121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma.
    Simpson KJ; Dugan AS; Mercurio AM
    Cancer Res; 2004 Dec; 64(23):8694-701. PubMed ID: 15574779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
    Kaushal N; Durmaz YY; Bao L; Merajver SD; ElSayed ME
    Mol Pharm; 2015 Jul; 12(7):2406-17. PubMed ID: 26020100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter.
    Baillat D; Leprivier G; Régnier D; Vintonenko N; Bègue A; Stéhelin D; Aumercier M
    Oncogene; 2006 Sep; 25(42):5764-76. PubMed ID: 16652151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.